<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010075</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068439</org_study_id>
    <secondary_id>FRE-GERCOR-SAM-S99-1</secondary_id>
    <secondary_id>EU-20028</secondary_id>
    <nct_id>NCT00010075</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer</brief_title>
  <official_title>Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one chemotherapy drug may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      older women who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the survival without degradation of quality of life in elderly women with&#xD;
           metastatic breast cancer treated with leucovorin calcium, fluorouracil, and&#xD;
           mitoxantrone.&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of response and survival without&#xD;
           progression, in these patients.&#xD;
&#xD;
        -  Determine the tolerance of these patients to this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive mitoxantrone IV and leucovorin calcium IV over 2 hours on day 1. Patients&#xD;
      then receive fluorouracil IV over 46 hours on days 1-2. Treatment repeats every 21 days for a&#xD;
      maximum of 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, after 3 courses, and at treatment completion.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the breast&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
               -  At least one non-irradiated lesion that is at least 2 cm in the greater diameter&#xD;
                  OR&#xD;
&#xD;
               -  Serous drainage, cutaneous metastasis, osseous metastasis, etc.&#xD;
&#xD;
          -  No symptomatic cerebral metastasis&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  75 to 90&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Alkaline phosphatase less than 3 times normal&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  Transaminases less than 3 times normal&#xD;
&#xD;
          -  Total protein greater than 60%&#xD;
&#xD;
          -  Albumin greater than 30 g/L&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 50% by echocardiogram or scintigraph&#xD;
&#xD;
          -  ECG normal&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other medical illness or condition that would preclude study&#xD;
&#xD;
          -  No other prior malignancy except basal cell skin cancer or curatively treated&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychological, social, familial, or geographical reasons that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No prior adjuvant anthracyclines&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  One or two prior regimens of hormonal therapy allowed for metastatic disease&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for metastatic disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent participation in another study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Carola, MD</last_name>
    <role>Study Chair</role>
    <affiliation>C.H. Senlis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Metz</city>
        <zip>55038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medico-Chirurgical Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

